CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients. | Gynecol Oncol;94(2): 340-51, 2004 Aug. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients.

Gordon, Alan N; Schultes, Birgit C; Gallion, Holly; Edwards, Robert; Whiteside, Theresa L; Cermak, Jennifer M; Nicodemus, Christopher F.

Affiliation

Gordon AN; U.S. Oncology, Texas Oncology PA, Dallas, TX 75246, USA. agordonmd@earthlink.net

Gynecol Oncol ; 94(2): 340-51, 2004 Aug.

Article in En | MEDLINE | ID: mdl-15297171

Subject(s)

Search on Google

Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / T-Lymphocytes / CA-125 Antigen / Antibodies, Monoclonal / Neoplasm Recurrence, Local Limits: Aged / Female / Humans / Middle aged Language: En Journal: Gynecol Oncol Year: 2004 Document type: Article Affiliation country: Country of publication:

Search on Google

Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / T-Lymphocytes / CA-125 Antigen / Antibodies, Monoclonal / Neoplasm Recurrence, Local Limits: Aged / Female / Humans / Middle aged Language: En Journal: Gynecol Oncol Year: 2004 Document type: Article Affiliation country: Country of publication: